Alexion launches a duo of new therapies for ultra-rare diseases in the EU

02/09/2015 - 2 minutes

Thanks to Alexion Pharmaceuticals, two ultra-rare diseases finally got the first treatment in the European Union, namely Lysosomal acid lipase deficiency (LAL-D) and Pediatric-onset hypophosphatasia. 

Alexion ramps up its product-pipeline. Until now, the Connecticut-based company, which comprises a market cap of about $38.5Bn (€34,2Bn), has lived mostly on sales of Soliris, the most expensive drug on the planet (up to $700,000 a year). In just the second quarter of 2015, Soliris cashed in $636M ($566M).

However, the biotech just proved it is not a one-hit-wonder. After they got positive feedback from the EMA in July, two therapies treating respective Pediatric-onset hypophosphatasia and Lysosomal acid lipase deficiency become the first approved treatment in the European Union. Fewer than 20 out of 1 million people are affected by the diseases, but those who are unlucky suffer devastating consequences.

LAL-D is caused by a genetic mutation that leads to the loss of LAL enzyme activity across multiple tissues. Without it, cholesteryl esters and triglycerides are not removed and can lead to multi-organ damage and premature death.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!